Check 35,000+ stocks against 26 valuation models and 37 quality factors

China Medical & HealthCare Group Limited (COLRF) fair value: what the stock is really worth

As of Aug 14, 2026: fair value of China Medical & HealthCare Group Limited $0.08, price $0.08, upside +0.0%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Healthcare · US · Home Hong Kong

Thin data Sep 24, 2026

China Medical & HealthCare Group Limited

COLRF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0800 · Fairly valued (+0.0%)

!Quality 34/100

!Mixed Growth (revenue 5y +6.2 %/yr)

!Loss-making · -1.6% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (3/10)

!Narrow moat 18/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0800 to bull $0.0880 Growth analysisrevenue history, year by year Quality 34/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch China Medical & HealthCare Group Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0001 – $1.45 · fair‑value band $0.0800 – $0.0880 · the $0.0800 price screens below the $0.0800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow China Medical & HealthCare Group in your weekly email

Every Wednesday you see whether China Medical & HealthCare Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tian An Medicare Limited, an investment holding company, primarily operates hospitals in the People's Republic of China and Hong Kong. It operates through Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments segments. The company is also involved in property development of independent living units and project management of health campus with a focus on eldercare and retirement community including elderly nursing home, service apartments, independent living units and commercial area comprising shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and lands; leases properties; and provides loan financial and healthcare services, as well as trading of securities listed in overseas exchange. The company was formerly known as China Medical & HealthCare Group Limited and changed its name to Tian An Medicare Limited in April 2024. Tian An Medicare Limited was incorporated in 1989 and is based in Wan Chai, Hong Kong. The company operates as a subsidiary of Tian An China Investments Company Limited.

Stock analysis

China Medical & HealthCare Group Limited (COLRF) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0800, so the stock looks roughly fairly valued today (gap 0.0%).

Valuation

Bull case: the Asset-Based group reads highest at a median of $0.1500 per share, and 4 of the 6 models we run sit above the $0.0800 price.

Bear case: the Earnings-Based group reads lowest at $0.0800, and 2 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0800 (bear) to $0.0880 (bull), the price of $0.0800 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

China Medical & HealthCare Group Limited reported revenue of HK$1.6B in FY2025 versus HK$1.5B in FY2021, a compound +2.6%/yr. Reported net income was −HK$26.8M in FY2025.

Key figures

Market cap $86.5M · P/S ratio 0.05 · Net margin −1.6% · Return on equity −1.1% · Return on assets (EBIT) 0.9% · Operating margin 2.8% · Revenue (TTM) HK$1.6B · Revenue growth (YoY) +6.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 0%, COLRF screens richer than that median.

Fair Value models

Bear $0.0800 Fair Value $0.0800 Bull $0.0880

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

EPV $0.0700 $0.0800 $0.0800 74

ROIC Compounder $0.0700 $0.0800 $0.0800 70

EV/EBITDA $0.2300 $0.3000 $0.3600 67

All 6 models by family

Earnings-Based

EPV $0.0700 $0.0800 $0.0800 74

Multiples

EV/EBIT $0.1200 $0.1500 $0.1800 66

EV/EBITDA $0.2300 $0.3000 $0.3600 67

EV/Revenue $0.1000 $0.1300 $0.1500 54

Asset-Based

NCAV (Graham) $0.1100 $0.1500 $0.2200 54

Economic Profit

ROIC Compounder $0.0700 $0.0800 $0.0800 70

Open the full fair value analysis →

Notify me when COLRF reaches fair value

Put COLRF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 34/100

Of which business quality 35 · Market factors (momentum, volatility) 56

Profitability 15

Margins and returns on capital today

Quality Growth 40

Are margins and returns improving?

Cashflow 13

Earnings quality: real cash, not paper profit

Fin. Strength 48

Balance sheet, leverage, solvency risk

Investment 69

Disciplined investing over empire-building

Low Volatility 98

Calm price path (market factor)

Momentum 40

Price trend over the last 3–12 months (market factor)

52W Momentum 33

Distance to the 52-week high (market factor)

Net Issuance 42

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+0.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.2%

Start year 2020 (pandemic). Over 10 years: −3.7% a year

Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.9%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−1.1% (2020) → 3.2% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch COLRF, get fair value alerts →

Compare China Medical & HealthCare Group Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 3/9 measures

Overall it trails its industry peers.

Valuation

Quality Score 34 · Bottom 25%

Fair Value upside −44.0% · Bottom 25%

Profitability

Return on assets 1.1% · Bottom 25%

Net margin (TTM) −1.6% · Bottom 25%

Operating margin (TTM) 2.8% · Bottom 25%

Growth and dividend

Revenue growth 6.1% · Above median

Balance sheet

Debt / equity 0.25× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.05× · Cheapest 25%

P/S (TTM) 0.05× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 34

FUTURE (revenue growth)31 · sector 26

PAST (return on equity)0 · sector 31

HEALTH (low debt)88 · sector 90

DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc HCA	$431.63	$597.97	+39%
Fresenius SE FRE	€43.64	€34.49	−21%
Dr. Sulaiman Al Habib Medical Services Group 4013	225.00 SAR	109.45 SAR	−51%
Tenet Healthcare Corporation THC	$257.93	$274.35	+6%
IHH Healthcare Berhad, an investment holding company, 5225	8.03 MYR	4.87 MYR	−39%
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,889	₹2,908	−67%
Encompass Health Corporation EHC	$123.47	$94.47	−23%
Fresenius Medical Care AG FMS	$22.27	$45.84	+106%
DaVita Inc DVA	$178.07	$215.81	+21%
Aier Eye Hospital Group 300015	¥7.91	¥10.86	+37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Medical & HealthCare Group Limited · Fair Value
$0.0800 +0%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/COLRF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">China Medical &amp; HealthCare Group Limited · Fair Value</span><br><b style="font-size:20px">$0.0800</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+0%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "China Medical & HealthCare Group Limited Fair Value". https://www.fairvalue-calculator.com/stock/COLRF

Frequently asked questions

Is China Medical & HealthCare Group Limited (COLRF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $0.0800 versus the last price from Aug 14, 2026 of $0.0800, about +0% upside (fairly valued).

What is the fair value of COLRF?

Our model-based fair value for China Medical & HealthCare Group Limited is $0.0800 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Aug 14, 2026): $0.0800.

What is the quality score of COLRF?

China Medical & HealthCare Group Limited has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for China Medical & HealthCare Group Limited (COLRF)?

Our model-based price target is the fair value of $0.0800 (as of Sep 24, 2026) from 6 valuation models. Cautious scenario $0.0800, optimistic scenario $0.0880. It is a calculation from audited fundamentals, not an analyst target.

What is the China Medical & HealthCare Group Limited stock forecast for 2026?

Our models put fair value at $0.0800, about +0% upside versus the last price from Aug 14, 2026 of $0.0800 (fairly valued). Cautious scenario $0.0800, optimistic scenario $0.0880. The calculation is refreshed regularly with new filings.

What is the revenue of China Medical & HealthCare Group Limited (COLRF)?

China Medical & HealthCare Group Limited reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of China Medical & HealthCare Group Limited (COLRF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Medical & HealthCare Group Limited it is $0.0800 per share (as of Sep 24, 2026), against a price of $0.0800. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).

Is China Medical & HealthCare Group Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, COLRF trades below its calculated fair value: price $0.0800, fair value $0.0800, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of COLRF?

No. The price is what the market pays today ($0.0800); the fair value is what the company's own numbers justify ($0.0800). For China Medical & HealthCare Group Limited the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.

How much is China Medical & HealthCare Group Limited worth?

The market values China Medical & HealthCare Group Limited at about $86.5M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0800; our models calculate a fair value of $0.0800 per share.

What do the bullish and bearish scenarios say about COLRF?

Our models span a range for China Medical & HealthCare Group Limited: cautious scenario $0.0800, base $0.0800, optimistic $0.0880 per share (as of Sep 24, 2026, price $0.0800). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of China Medical & HealthCare Group Limited (COLRF)?

Balance-sheet figures for China Medical & HealthCare Group Limited (as of Sep 24, 2026): return on equity −1.1%, debt of 0.25 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.

How far is COLRF from its 52-week high?

China Medical & HealthCare Group Limited trades at $0.0800, at its 52-week high of $0.0800 and at the low of $0.0800 (as of Aug 14, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0800 is for.

Which stocks are comparable to China Medical & HealthCare Group Limited?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is China Medical & HealthCare Group Limited stock attractive at the current price?

The data as of Sep 24, 2026: price $0.0800, calculated fair value $0.0800 (+0%), Quality Score 34/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of COLRF calculated?

We run China Medical & HealthCare Group Limited through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0800, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. China Medical & HealthCare Group Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of China Medical & HealthCare Group Limited (COLRF)?

The latest price we hold is from Aug 14, 2026 and stands at $0.0800. Our model-based fair value is $0.0800, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with China Medical & HealthCare Group Limited right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0800 to $0.0880), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Where does the earnings growth of China Medical & HealthCare Group Limited (COLRF) come from?

Earnings per share at China Medical & HealthCare Group Limited grew −32.9 % a year from 2013 to 2024. Broken into its drivers: revenue per share +7.3 %, EBIT margin −9.5 %, tax rate −5.3 %, residual (interest, one-offs) −27.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of China Medical & HealthCare Group Limited

How large is the market capitalisation of China Medical & HealthCare Group Limited (COLRF)?

The market capitalisation of China Medical & HealthCare Group Limited is $86.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of China Medical & HealthCare Group Limited (COLRF)?

The price-to-sales ratio of China Medical & HealthCare Group Limited is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of China Medical & HealthCare Group Limited (COLRF)?

The net margin of China Medical & HealthCare Group Limited is −1.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of China Medical & HealthCare Group Limited (COLRF)?

The return on equity (ROE) of China Medical & HealthCare Group Limited is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of China Medical & HealthCare Group Limited (COLRF)?

On an EBIT basis the return on assets of China Medical & HealthCare Group Limited is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of China Medical & HealthCare Group Limited (COLRF)?

The operating margin of China Medical & HealthCare Group Limited is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at China Medical & HealthCare Group Limited (COLRF)?

Revenue at China Medical & HealthCare Group Limited is growing +6.1% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at China Medical & HealthCare Group Limited (COLRF)?

Earnings per share at China Medical & HealthCare Group Limited are growing −44.6% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does China Medical & HealthCare Group Limited (COLRF) generate?

The free cash flow of China Medical & HealthCare Group Limited is −HK$69.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does China Medical & HealthCare Group Limited (COLRF) carry?

The net debt of China Medical & HealthCare Group Limited is HK$149M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch China Medical & HealthCare Group Limited in the live analysis

One click puts China Medical & HealthCare Group Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.